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ABSTRACT  
Hepatocellular carcinoma (HCC) is a devastating and prevalent cancer with limited 
treatment options. Technological advances have enabled genetic screens to be employed 
in HCC model systems to characterize genes regulating tumor initiation and growth. 
Relative to traditional methods for studying cancer biology, such as candidate gene 
approaches or expression analysis, genetic screens have several advantages: they are 
unbiased, with no a priori selection, can directly annotate gene function, and can uncover 
gene-gene interactions. In HCC, three main types of screens have been conducted and 
are reviewed here: (1) Transposon-based mutagenesis screens, (2) knock-down screens 
using RNA interference (RNAi) or the CRISPR/Cas9 system, and (3) overexpression 
screens using CRISPR activation (CRISPRa) or cDNAs. These methods will be valuable 
in future genetic screens to delineate the mechanisms underlying drug resistance and to 
identify new treatments for HCC. 
 
Main Concepts and Learning Points 
 Genetic screens in animal models shed light on functional alterations in HCC 
 Advances in sequencing technology allow for increasingly complex screens  
 Liver genetic screens are revealing the heterogeneity of genetic alterations in HCC 
patients  
 Future work may apply genetic screening to discover new treatments for HCC 
  
HCC is a unique cancer that needs unique approaches to treatment 
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related 
mortality worldwide and is growing in incidence1,2. HCC is unique among cancers: a 
recent analysis of 17 human cancer types revealed substantial overlap in the gene 
expression patterns of all the cancers with the single exception of HCC3. This is consistent 
with the observation that several treatments, though effective against other cancers, have 
largely failed to improve outcomes for patients with HCC4. Therefore, the discovery of 
new treatments will depend on the development of models that accurately recapitulate 
HCC.  
Most cases of HCC arise in cirrhotic livers; hence it is not surprising that several 
major underlying risk factors are characterized by chronic liver injury. Worldwide, the most 
common etiologies are chronic hepatitis B or C infections. Though the prevalence of these 
infections is decreasing in many countries due to the availability of an effective vaccine 
and treatment, the incidence of Hepatitis C-associated HCC in the United States is still 
not falling due to a large number of ‘baby boomers’ who have been chronically infected 
for decades. Non-alcoholic fatty liver disease is also rising in incidence in Western 
countries and is likely to soon overtake Hepatitis C as the major cause of HCC in the 
United States5–7. Additional etiologies of HCC include biliary tract diseases and exposure 
to toxins such as alcohol.  
The advent of high throughput sequencing (HTS) technology has accelerated the 
identification of mutations and gene expression changes in cancers. The genomes of 
thousands of patients’ cancers have been sequenced to date, including hundreds of 
HCCs (a large collection of data is available publicly from the Cancer Genome Atlas at 
http://cancergenome.nih.gov/). These data have helped define the diverse genetic 
landscape of mutations and expression changes that occur in HCCs8–11. Nevertheless, 
additional complementary data are necessary to provide evidence of causation, i.e. that 
genetic changes induce tumor formation rather than occurring secondarily during the 
process of cancer development12.  
HCC is challenging to treat due to several factors including its genetic diversity, 
the underlying liver dysfunction in most patients, the difficulty in detecting early stage 
disease, and the lack of effective treatments. Only 30% of patients with HCC are eligible 
for potentially curative interventions like liver transplantation at the time of diagnosis13. In 
general, classical chemo- and radiotherapies have either low efficacy or undesirable 
toxicity4,13. Only a single drug is approved in the United States to treat HCC as a first-line 
therapy: sorafenib, a multi-specific kinase inhibitor14,15. Sorafenib treatment has a 
marginal median survival benefit of just 2-3 months, and there are no good predictors of 
response16. In patients whose disease progresses during sorafenib treatment, second-
line options were recently approved. One is another multikinase inhibitor, regorafenib, 
which improves survival over placebo by just under three months17. The other second-
line option is Nivolumab, an immune-therapeutic with remarkable efficacy in a fraction of 
patients18–20. However, the search must continue for more broadly-effective therapies.  
The goal of this review is to provide an overview of how innovations in gene 
delivery and in genetic screening technology in mice can significantly expand our 
knowledge of the genes driving or modulating the development of HCC, which can be 
applied to discover new therapeutic targets. The main methods and most notable studies 
are summarized in Table 1. 
 Genetic screens are a powerful method for annotating gene function 
 A genetic screen is an assay in which the genetic codes are mutated or gene 
expression is systematically perturbed in order to identify which changes result in a 
phenotype of interest21. Whole organism genetic screening has been employed frequently 
in the nematode Caenorhabditis elegans, in the fruit fly Drosophila melanogaster, in the 
zebrafish Danio rerio, and in mice (reviewed in 22). Internet resources for many model 
organisms, including wormbase.org, flybase.org, and ZFIN.org, catalog detailed 
information linking specific genetic changes to precise phenotypic manifestations. 
Screens have used a variety of methods to manipulate gene expression, including 
chemical mutagenesis, transposon insertional mutagenesis, RNA interference (RNAi), 
complementary DNA (cDNA) expression, and the prokaryotic clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) 
system. More recent efforts have combined genetic screens with chemical library screens 
to explore therapeutic potential or identify mechanisms responsible for drug efficacy22. 
While useful in identifying phenotypes in a whole organism, these types of studies do not 
easily translate to complex, tissue-specific human diseases such as HCC.  
 Genetic screens in cancer cells can provide mechanistic evidence linking genetic 
changes to the important phenotypes of tumor initiation, morphology, growth, or drug 
sensitivity or resistance. Specific functional insights, as compared to correlative genetic 
associations, better facilitate therapeutic development and selection.  
To efficiently identify cancer-driving genes, transposon mutagenesis, cDNA, RNAi, 
and CRISPR screens all heavily rely on high-throughput sequencing (HTS). For 
transposon mutagenesis, the molecular readout is the flanking genomic sequence, which 
precisely identifies the insertion site of the transposon. cDNA screens may use barcoding 
of plasmids to enable precise quantification of the proportion of plasmids before and after 
the screen23. RNAi and CRISPR screens depend on identifying and quantifying the RNA 
coding sequences. 
Data generated by genetic screens in mice can be integrated with the large 
collection of available human cancer databases to provide insights into the multiple 
alterations found in HCC. Such studies can significantly contribute to the identification of 
potential new drug targets and to the ability to predict which signals should be targeted in 
patients.  
 
Mouse models of HCC 
 While most strains of mice do not spontaneously develop HCC, liver cancer in mice 
can be induced through chemical stimulus, transplantation of tumor cells, or genetic 
alteration. Administration of the chemical diethylnitrosamine (DEN) causes DNA damage, 
which leads to the formation of tumors by proliferating hepatocytes harboring mutations. 
DEN does not induce tumorigenesis in adult mice unless it is combined with an additional 
toxin, such as carbon tetrachloride (CCl4), a hepatotoxin that triggers inflammation and 
fibrosis. Chemical stimulus is also frequently used in combination with genetically 
engineered mouse models (GEMMs) of HCC. 
A number of GEMMs have been generated to study tumorigenesis in the liver. Due 
to the numerous etiologies contributing to hepatocellular carcinogenesis, no single GEMM 
is capable of completely recapitulating the disease. However, by reproducing genetic 
alterations that are common in HCC (Figure 1A), such as by inactivating tumor 
suppressors, including transformation related protein 53 (Trp53) and adenomatous 
polyposis coli (Apc), or ectopically expressing oncogenes, including Myc and catenin beta 
1 (Ctnnb1), in hepatocytes, transgenic mice develop tumors that mimic features of the 
disease (reviewed in 24–27). 
The use of GEMMs for combinatorial studies has led to the discovery of important 
genetic synergisms, such as concomitant MYC and transforming growth factor  (TGF) 
overexpression, which accelerates liver carcinogenesis28. A GEMM with temporally 
controlled oncogene expression was used to demonstrate that activated MYC drives the 
development of HCC and that MYC-driven tumors involute when MYC expression is 
removed29. Several mouse models carrying alterations of receptor tyrosine kinase (RTK) 
signaling components recapitulate alterations frequently observed in HCC patient 
subgroups, including transcriptional, epigenetic, and signaling modifications. Recently, a 
unique genetic system found that mice with slightly enhanced wild-type MET expression 
(Alb-R26Met mice) spontaneously develop HCC, illustrating a striking vulnerability of the 
liver to subtly increased RTK levels30.  
The downside of the GEMM approach is that models can take months to develop 
and often require complicated breeding schemes in order to examine gene-gene 
interactions in cancer development. Furthermore, the expression of oncogenes may not 
be restricted to the adult stage of development, as the promoters – most commonly alpha-
fetoprotein (AFP) or albumin (Alb) – may be active during early liver development, unless 
expression is controlled with inducible systems such as tTA/TRE or Cre-LoxP (Figure 
1A). Thus, while transgenic mouse models are useful in studying liver cancer, several 
technical challenges must be taken into consideration prior to implementation.  
A powerful method for transgene delivery to the mouse liver is the hydrodynamic 
tail vein injection (HTVI) technique (Figure 1B)31–34. HTVI introduces DNA sequences 
into the nuclei of up to 40% of hepatocytes upon the injection of a large volume of the 
DNA in saline or lactated ringer’s solution (a 1:10 ratio of volume to mouse mass) into the 
tail vein of mice. The solution is delivered rapidly, in fewer than 10 seconds, which is 
believed to cause a transient right-sided venous congestion that engorges and floods the 
liver with fluid and mechanically disrupts cell membranes35–39. The technique is highly 
specific to hepatocytes, with little expression in other cell types of the liver or in other 
organs. When the HTVI technique is used to inject plasmids encoding transposon 
systems such as Sleeping Beauty (SB)37,40,41, piggyBac (PB)42, or Tol243, the transposon 
sequences and the “cargo” – i.e. the genes of interest – are integrated into the hepatocyte 
genome, which enables stable expression for the life of the cell. This achieves stable 
integration in 0.1% to 2% of all hepatocytes with SB37,44. In an adult mouse there are 
roughly 108 hepatocytes; therefore, HTVI of transposons could in theory examine more 
than 106 independent clonal events in a single mouse45. 
 In previous studies of liver cancer, HTVI was used to transfect hepatocytes in vivo 
in order to assess the effects of specific changes in gene expression on tumorigenesis. 
For example, in one study, wild type mice underwent HTVI with an SB-overexpression 
plasmid encoding activated thymoma viral proto-oncogene 1 (Akt), which was stably 
integrated into the hepatocyte genomic DNA46. The upregulation of AKT induced 
increased lipogenesis and hepatocarcinogenesis. A subsequent study in which an SB-
overexpression plasmid encoding the intracellular domain of the NOTCH1 receptor was 
coinjected with the AKT overexpression plasmid showed that intrahepatic 
cholangiocarcinomas arise from mature hepatocytes that have undergone malignant 
transformation and not from biliary epithelial or liver progenitor cells47. These studies 
discovered mechanisms of HCC tumorigenesis and pointed toward new target genes for 
the development of new therapies. Thus, HTVI is a powerful alternative to generating 
genetically modified animals in order to study the role of hepatocytes in liver cancer. 
In combination with HTVI, a useful tool for performing high throughput genetic 
screens in the mouse liver is the murine genetic model of hereditary tyrosinemia type 1 
(HT-1)48. Humans with HT-1 have mutations in the gene encoding fumarylacetoacetate 
hydrolase (FAH), an enzyme required for proper tyrosine metabolism. Lack of FAH 
activity results in severe liver injury from the accumulation of the toxic metabolite 
fumarylacetoacetate (FAA) in hepatocytes. The drug nitisinone (chemical name 2-(2-
nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione, or NTBC) restores healthy liver 
function in HT-1 patients by inhibiting an upstream enzyme in tyrosine catabolism and 
preventing the formation of FAA49. 
In the Fah-/- mouse, liver toxicity can be alleviated by the stable genomic integration 
of a transgene encoding the functional FAH enzyme32,44. Transposons expressing Fah 
are delivered by HTVI to Fah-/- mice that have been continuously administered nitisinone, 
which is then withdrawn to induce liver injury and create a selective environment for any 
Fah-corrected hepatocytes to repopulate the liver. Although the initial integration of the 
Fah transgene by SB transposase is estimated to occur in approximately 0.1-2% of 
hepatocytes, these FAH-positive cells are able to expand and restore liver function 
without tumor formation44. The rescue of Fah-null hepatocytes by functional FAH 
expression has been leveraged to perform genetic screens by linking a functional copy of 
Fah to libraries of cDNAs, short hairpin RNAs (shRNAs), or guide RNAs (gRNAs) in order 
to study their effects on liver repopulation and cancer41,50,51.  
 
Transposon-based mutagenesis 
Several forward genetic screens aimed at identifying HCC drivers have been 
performed via the mobilization of mutagenic transposons by the SB transposase (Figure 
2). SB excises transposon DNA that is flanked by inverted repeat/direct repeat sequences 
and reintegrates the transposon at random TA target dinucleotides52. The system is well-
suited for insertional mutagenesis screens in mice using engineered transposon DNA 
cassettes, as the transposase is highly active in mammalian cells.  
Three different iterations of the SB mutagenic transposon have been engineered, 
T2/Onc, T2/Onc2, and T2/Onc3, all of which are capable of inducing both gain- and loss-
of-function mutations depending on the orientation of their insertion relative to coding 
sequence. These transposons all comprise the following elements: (a) a strong promoter 
and enhancer followed by a splice donor site, (b) a splice acceptor site joined to a 
polyadenylation signal positioned upstream of the promoter/enhancer in the sense 
orientation, and (c) a second splice acceptor site joined to a polyadenylation signal, which 
is positioned downstream of the promoter/enhancer in the antisense orientation (Figure 
2). Integration of a transposon cassette in the sense orientation can drive overexpression 
of downstream coding sequence, while its insertion in either orientation downstream of 
coding sequence truncates the transcript. By altering the gene sequence, the transposon 
mutagenesis system can uncover genomic mutations that lead to oncogenic 
transformation, a unique advantage over RNAi or cDNA screens, which instead aim to 
modulate expression levels of endogenous genes. 
Thousands of disruptive transposition events can occur in a tissue expressing the 
SB transposase as a consequence of multiple transposon mobilizations from the parent 
transposon concatemer53–55. Sites where transposons integrate more often than would 
be expected by chance in independent tumors are termed common insertion sites (CISs). 
Potential drivers of tumorigenesis are identified based on increased frequency of CISs in 
tumors, which is indicative of selection for a tumorigenic event. 
The first version of the SB mutagenesis screen used the SB/T2Onc transposon in 
a p19Arf-deficient (Arf-/-) mouse strain that ubiquitously expresses the SB transposase 
(SB10). The majority of mice formed tumors, mostly sarcomas, by 6 months of age. The 
most common CIS identified was in the ninth intron of Braf, an alteration predicted to 
produce a constitutively activated form of this known oncogene. This result demonstrated 
that SB insertional mutagenesis can identify disease-causing mutations that synergize 
with common mutations in cancer models53. 
Subsequent refinements made to the SB-T2/Onc system have improved its ability 
to promote tumorigenesis. The second-generation mutagenic transposon (T2/Onc2) 
included a larger splice acceptor and optimized SB transposase binding sites, along with 
an improved SB allele (SB11). T2/Onc2;SB11 mice showed insertional mutations at the 
embryonic stage, exhibited high prenatal lethality, and spontaneously developed up to 
three separate, metachronous tumors by 17 weeks of age, the most common of which 
were T-cell lymphomas54. However, when investigating epithelial-derived tumors, this 
high frequency of lymphomas is undesirable. To increase the frequency of carcinomas, 
the chicken β-actin (CAG) promoter, which is highly active in epithelial cells, was 
introduced in the T2/Onc3 system55. This change increased the frequency of tissue-
specific carcinomas, including HCC. More recently, the Rosa26-lsl-SB11 mouse was 
developed to enable spatial and temporal activation of SB11 allele using Cre recombinase 
enzyme56. 
To identify mutations that synergize with loss of function of tumor protein 53 (TP53; 
ortholog of mouse Trp53), which is often mutated in human HCCs, insertions of T2/Onc 
were screened in mice expressing a dominant negative Trp53 specifically in the liver56. 
Similar to what was seen in the Arf-/- genetic background, mice expressing mutant Trp53 
together with the transposon/transposase displayed a significantly increased tumor 
burden compared to mice expressing mutant Trp53 alone. Importantly, as is observed in 
human HCC, there was a strong sex bias toward male mice, which showed greater tumor 
incidence and decreased latency. Epidermal growth factor receptor (Egfr) had the highest 
number of insertions, most of which truncated the transcript and resulted in increased 
kinase activity of the translated protein56. HCC tumors in males displayed higher rates of 
chromosome 7 polysomy (the locus encoding EGFR) and higher EGFR mRNA levels 
compared to females, suggesting elevated susceptibility to EGFR-driven HCC in male 
patients57. As both p53 and EGFR are linked to human HCC, these results are noteworthy 
and suggest that simultaneous dysregulation of these genes can promote HCC in a sex-
specific manner. 
 Transposon insertional mutagenesis has also been used to examine epithelial-
mesenchymal transition (EMT), which is thought to play a prominent role in HCC 
metastasis and resistance to cancer drugs like sorafenib58. Kodama et al. generated 
immortalized hepatoblast cell lines from fetal liver cells harvested from mice with liver-
specific transposase activation. When injected into the flanks of immunodeficient mice, 
these cells produced tumors that coexpressed epithelial and mesenchymal markers, 
including Epcam and vimentin, respectively, despite their epithelial origin. The authors 
examined CIS-associated genes from the tumors using KEGG pathway analysis and 
identified the involvement of pathways already known to be involved in EMT, supporting 
the accuracy of their model. Unexpectedly, however, the most highly enriched pathway 
was ubiquitin-mediated proteolysis, which was not previously associated with EMT. The 
authors went on to confirm that this pathway is involved in EMT using in vitro assays, and 
showed that inactivation of the HUWE1, KDM6A, and PTPN12 tumor suppressors led to 
the EMT phenotype of sorafenib resistance. Thus, the use of an insertional mutagenesis 
screen led to the identification of candidate genes driving EMT in human HCC58. 
 Although clinically relevant discoveries have been made through SB transposon 
insertional mutagenesis, the system has several drawbacks. One disadvantage is the 
long latency to tumor development, which can take well over 100 days53,57,59. Additionally, 
the system requires that engineered mice express the mutagenic transposon, the 
transposase, and a liver-specific Cre recombinase for the system to be functional. 
Performing these screens on a cancer-predisposed genetic background adds another 
layer of complexity. Furthermore, in order to obtain sufficient statistical power, large 
cohorts of mice must be used. For example, a screen by Collier et al. utilized 64 
T2/Onc;SB10;Arf-/- animals53. Given the complicated mating schemes required for such 
experiments, obtaining sufficient animals of the correct genotype requires significant effort 
and time. 
Another issue to consider while implementing insertional mutagenesis screens is 
the “local hopping” phenomenon in which transposition is more likely to occur near the 
locus of the parent concatemer (the series of multiple plasmids inserted into a genomic 
locus), than would be expected by chance. Insertions that occur on the same 
chromosome as the parent transposon concatemer must be excluded in downstream 
analysis of CIS loci to reduce false-positive CISs, except when supported by another 
transposon line in which the concatemer is located on a different chromosome. The 
exclusion of a chromosome from analysis imposes limits on the ability to fully exploit the 
findings of a screen. For example, in a study using SB and T2/Onc2 to identify drivers of 
liver tumorigenesis in the context of HBV surface antigen (HBsAg) expression, CISs 
identified in chromosome 1 were filtered from the results to account for local hopping60. 
Thus, a large number of genes on chromosome 1, a gene-rich chromosome harboring 
the orthologs of numerous known human cancer genes, could not be assessed. 
Therefore, a follow-up screen was performed in HBsAg mice in which the transposons 
were mobilized from a transposon concatemer located on chromosome 961. As an 
alternative to SB, the PB transposon system has less local hopping and may be an 
improved insertional mutagenesis transposon system, but it has not yet been 
characterized in HCC models62. 
Collectively, these studies using SB to study HCC have shown that the 
identification of candidate cancer genes is dependent on the components and genetic 
background used in the screen. A comprehensive comparison of the genes identified by 
several SB HCC screens found dissimilarities in sample number, genetic background, SB 
transposon version, sequencing, and bioinformatics methodologies63. Despite these 
limitations, eight candidate genes were identified as significantly enriched for transposon 
insertions in at least five of the eight SB-induced HCC models examined63. Human 
homologs of three of the genes, staphylococcal nuclease and tudor domain containing 1 
(Snd1), StAR-related lipid transfer (START) domain containing 13 (Stard13; also known 
as deleted in liver cancer 2), and thyroid hormone receptor interactor 12 (Trip12), have 
already been implicated in HCC64–66. Two other candidate genes, dihydropyrimidine 
dehydrogenase (Dpyd) and glycogen synthase kinase 3 beta (Gsk3b) may mediate tumor 
chemoresistance67,68. While the relevance of these eight genes to HCC is not yet entirely 
clear, the regularity with which they are associated with CISs, as well as previous studies 
linking many to cancer, strongly supports their involvement in the disease. Future studies 
will be needed to identify cooperative interactions, genetic context dependence, and 
strengths of these candidate genes as drivers of HCC. Mapping of cooperative 
interactions has been described in mouse models of lung adenocarcinoma69, in which a 
variety of tumor-predisposing GEMMs were used for CRISPR-based tumor suppressor 
inactivation screens in the lung to interrogate gene-gene interactions.  
 
RNAi screening 
 Rather than disrupting gene expression at the DNA level, RNA interference (RNAi) 
knocks down expression of specific genes by targeting degradation of their transcripts 
(Figures 1B and 3A). In an RNAi screen, mRNAs are targeted for degradation by RISC 
by base pairing with the processed products of shRNAs expressed from a vector library 
or small interfering RNAs (siRNAs) transfected as a pool into cells70. This method has 
been used in numerous large genetic screens in cancer cell lines to identify tumor 
suppressor genes and genes that confer resistance to drug treatment (reviewed in 71). 
RNAi screens have been performed in vivo to study liver cancer as well. Zender et 
al. tested the hypothesis that tumor suppressor genes are likely to reside in chromosomal 
regions that are deleted in HCC72. They first analyzed DNA copy number variations in 
100 human HCCs that resulted from different etiologies, then identified the mouse 
orthologs of the genes of interest in deleted regions. Candidate genes were targeted 
using mir30-based shRNA sequences. Pools of Retroviruses expressing shRNAs were 
used to infect Trp53-/- embryonic hepatocytes overexpressing MYC, which were then 
injected intrasplenically into mice to generate a “mosaic” liver. The tumor lesions resulting 
in these animals were collected in order to identify the shRNAs through sequencing. The 
most highly enriched shRNA targeted was exportin 4 (Xpo4), which follow-up studies in 
human HCC cell lines and tissues have confirmed functions as a tumor suppressor73,74. 
Xpo4 encodes exportin 4, which is required for the nuclear export of the signal 
transduction molecule SMAD3, a mediator of TGF- signaling75. Thus, this report 
demonstrated the utility of RNAi screens in identifying bona fide tumor suppressor genes. 
A separate investigation used the same shRNA library to identify gene targets that 
could increase the regenerative capacity of hepatocytes in the Fah-/- mouse model50. The 
shRNAs were subcloned into Fah-SB transposon plasmids. To further model chronic liver 
damage beyond the induction of tyrosinemia, following repopulation, the Fah-/- mice were 
treated for six weeks with CCl4. Hairpins targeting mitogen-activated protein kinase 
kinase 4 (Mkk4; also called Map2k4) became enriched several thousand-fold during both 
repopulation and CCl4 treatment. Furthermore, the hepatocytes of mice that were injected 
with an Mkk4-shRNA transposon and then underwent partial hepatectomy (PH) re-
entered the cell cycle more quickly than those that were injected with a noncoding shRNA 
transposon. Hepatocytes that expressed Mkk4-shRNA were also more resistant to 
induced apoptosis, had an increased proliferation rate, and an increased survival rate in 
vitro, after which they could repopulate the mouse liver. Notably, Mkk4-shRNA-
expressing mice did not develop Mkk4-shRNA-expressing tumors, even after a year50, 
illustrating how, in some genetic contexts, knockdown of a tumor suppressor can improve 
liver regeneration without causing cancer. 
In contrast to these studies examining genes that are deleted in HCC, Rudalska et 
al. targeted genes that undergo amplifications76. In an in vivo RNAi screen, HCC-
susceptible Arf-/- mice underwent HTVI with a plasmid expressing SB transposase and a 
transposon vector expressing oncogenic neuroblastoma ras oncogene (NrasG12V) plus a 
library of shRNAs against the genes of interest in order to uncover a possible mechanism 
leading to sorafenib resistance. Half of the mice receiving shRNA libraries were treated 
with sorafenib, while the other half were treated with vehicle. Notably, two mitogen-
activated protein kinase 14 (Mapk14) shRNAs were depleted over 100-fold in sorafenib-
treated livers, suggesting that Mapk14 expression promotes tumor growth and sorafenib 
resistance. Encouragingly, Arf-/- mice with tumor growth triggered by NrasG12V that were 
treated with a combination of sorafenib and the MAPK14 inhibitor BIRB796 had a lower 
tumor burden and longer survival than mice treated by sorafenib alone. Together, this 
suggests that sorafenib does not completely inhibit kinase signaling in rodent models and 
that the addition of a second kinase inhibitor is a potential strategy to treat HCC76. 
 RNAi screening has led to a better understanding of HCC mechanisms and 
possible treatments, but like insertional mutagenesis, it has limitations that must be 
considered. In particular, RNAi activation in vivo has the potential to overwhelm the 
endogenous RNAi machinery, leading to interference with normal microRNA processing 
that may be critical for hepatocyte function, causing severe hepatotoxicity77–79. 
Furthermore, there may be off-target effects from binding of shRNAs to similar target 
sequences. Therefore, all of the most promising hits from these screens must undergo 
extensive validation, such as with additional specific shRNAs80. A potential advantage of 
RNAi is that it could potentially translate to a direct therapeutic in the form of siRNAs that 
are targeted to genes in the liver (reviewed in 81). 
 
CRISPR-based screening 
Due to its ease of use, specificity, and scalability, the CRISPR/Cas9 system is now 
widely used for gene editing and to modulate endogenous gene expression in cancer 
studies, including studies on tumor initiation and progression in mice (Figure 3B).  
The CRISPR/Cas9 system was adapted from bacteria for genome and epigenome 
editing in eukaryotes (reviewed in depth in 82 and 83) and in genome-wide screens, 
particularly in cancer (reviewed in 84 and 85). Briefly, wild type Cas9 is an RNA-guided 
DNA endonuclease that forms a complex with a gRNA molecule, which then targets the 
complex to a complementary DNA sequence where it cleaves both strands of DNA. This 
system been adapted to target the induction of double strand breaks (DSBs) in order to 
precisely edit the genome by homology-directed repair, or to mutate the genome by 
insertion or deletions of local nucleotides (indels) introduced by non-homologous end 
joining82. A catalytically dead Cas9 (dCas9), which cannot cleave DNA, can be used to 
target genomic loci for activation (known as CRISPR activation, or CRISPRa) or for 
inhibition (known as CRISPR inhibition or CRISPRi). 
CRISPR screens performed in vitro are capable of identifying mediators of cell 
viability and potential drug targets in HCC. For example, a recent screen used the human 
genome-scale CRISPR knockout library version 2 (GeCKO v2), which comprises gRNAs 
targeting 19,050 genes, to perform a loss-of-function screen in human HCC-derived Huh7 
cells being treated with sorafenib86. Among cells that were resistant to sorafenib 
treatment, gRNAs targeting shugoshin 1 (SGOL1) were the most enriched, suggesting 
that expression of this gene is necessary for sorafenib to induce cell death. Intriguingly, 
the authors found that high SGOL1 expression in HCCs predicts worse survival. Future 
studies will need to examine whether patients with high SGOL1 are more likely to respond 
to sorafenib. Another recent screen used the HCC cell lines Hep3B and Huh7 and 
transduced them with a lentiviral gRNA library targeting the full complement of human 
kinases87. gRNAs targeting cyclin-dependent kinase 7 (CDK7) were significantly depleted 
in both cell lines, suggesting that this gene is essential for HCC cell survival. Consistent 
with these results, CDK7 is upregulated in human HCC, and the expression correlates 
with worse survival. Importantly, HCC cell lines and mouse HCC xenografts were 
sensitive to a CDK7 inhibitor as long as MYC was upregulated in these cells, which is 
consistent with previous studies of CDK7 inhibitors and MYC-driven cancer88–90. Thus, 
these studies highlight the power of in vitro screens to identify promising therapeutic 
targets, but the results must be validated by comparison to human data, such as datasets 
from TCGA, in order to determine their clinical relevance. 
A number of very large genetic screens using CRISPR have been performed in ex 
vivo transduced cancer cell lines, derived from leukemia, melanoma, intestine and lung, 
which could be xenografted into recipient mice to examine genes associated with 
phenotypes such as metastasis91–94. In these cases, the cell lines undergo a drug 
selection step to ensure that the gRNAs are linked to the resultant tumors, which can be 
easily sequenced and used as a surrogate for the genetic changes that become enriched 
in resultant tumors. The disadvantage of this approach is that these screens cannot 
examine tumor initiation, as the cells have already been transformed. 
An ex vivo knockout screen was performed by Song et al. using cancer 
predisposed Trp53-/- mouse embryonic liver progenitor cells expressing oncogenic MYC 
and Cas995. The cells were stably transduced with the mGeCKOa lentiviral library 
expressing gRNAs targeting 20,611 mouse genes and transplanted subcutaneously into 
nude mice. The relative enrichment of gRNAs in the resultant tumors was measured by 
high throughput sequencing of pre- and post-implantation cells, revealing significant 
enrichment of all three gRNAs for only one target, neurofibromin 1 (Nf1). Mutations in 
NF1 cause neurofibromatosis and have been reported in cholangiocarcinoma. To validate 
the function of Nf1 as a tumor suppressor in hepatocytes, the authors examined human 
HCC data and identified point mutations in NF1. Accelerated tumorigenesis in mice 
injected with plasmids encoding Myc, Cas9, and Nf1-gRNA in multiple tumor-predisposed 
genetic backgrounds further validated the tumor suppressor function of Nf1. Notably, 
HCC patients with low NF1 mRNA levels also had shorter survival times than those with 
high NF1 mRNA levels. Despite the clinical relevance of this discovery, tumor initiation 
may be influenced by the liver microenvironment. Thus, in vivo screens with the same 
lentiviral library may result in enrichment of gRNAs against a different set of targets95. 
In vivo modeling of oncogenesis using CRISPR systems has developed rapidly 
over the past few years. In a few of the first studies, mice were shown to develop lung 
cancer after intra-tracheal injection of viruses delivering CRISPR/Cas9 components that 
targeted a variety of tumor suppressor genes, caused chromosomal translocation, or 
activated Kirsten rat sarcoma viral oncogene homolog (Kras) via homology directed repair 
to a mutant form96–98. 
In the liver, HTVI of CRISPR plasmids targeting mutations in Trp53 and phosphate 
and tensin homolog (Pten) led to the development of liver tumors by 3 months99. The liver 
tumors had bile duct features that were similar to tumors that develop in mouse models 
of ablation of these two genes. CRISPR/Cas9 was also used to generate activated -
catenin, one of the most common features of HCC, by HTVI of plasmids providing Cas9, 
a gRNA targeting the -catenin gene, Ctnnb1, and a repair cassette to insert four 
activating point mutations into the gene via homology-directed repair. After injection, 
nuclear -catenin, a marker of activation, was detected in a number of hepatocytes, 
demonstrating the ability of CRISPR systems to model HCC99. 
The first true in vivo multiplexed CRISPR/Cas9 screen was performed by HTVI of 
plasmids into cancer predisposed KrasG12D mice100. The plasmids consisted of SB 
transposase and transposons containing a Cas9 expression cassette plus gRNAs 
targeting up to 18 different putative liver cancer genes. The mice developed multiple 
tumors by 20-30 weeks of age. Similarly, wild type mice injected with the Cas9-gRNA 
library and treated with CCl4 developed multiple tumors. Interestingly, the transposon 
sequences were found to be integrated in the genomic DNA of only 5% of tumors, 
indicating that transient gRNA expression could lead to tumor formation. Therefore, rather 
than determining the enrichment of the gRNA sequences in each tumor, the target sites 
were instead examined for indels. Numerous indels were found in each tumor, with 
significant enrichment of mutations at Pten and tet methylcytosine dioxygenase 2 (Tet2) 
loci, which was correlated with a cholangiocarcinoma-type tumor phenotype. Sequencing 
also showed that Cas9-induced large intrachromosomal deletions between gRNA target 
sites. Thus, this was the first demonstration that CRISPR/Cas9 could be used for a 
multiplexed screen in vivo to induce specific genetic mutations, and to correlate the 
genetic changes with the tumor phenotype. Importantly, however, the study highlighted 
the challenges to scaling up, as even transient gRNA expression could lead to dramatic 
changes to the genome. Use of larger gRNA libraries with wild type Cas9 would potentially 
require whole exome sequencing of tumors to characterize all of the target site changes, 
which is costly and labor-intensive.  
A large, fully in vivo loss-of-function CRISPR screen in HCC was performed by Xu 
et al. more recently101. They built a PB transposon library using the GeCKOv2 genome-
scale mouse CRISPR/Cas9 knockout library containing over 130,000 gRNAs targeting all 
mouse protein coding genes and miRNAs, which was delivered by HTVI to recipient mice 
together with vectors expressing cyclin dependent kinase inhibitor 2A (Cdkn2a)-gRNA 
and NrasG12V to accelerate tumorigenesis. This resulted in the development of tumors in 
9 out of 27 mice at 45 weeks. The gRNAs linked to tumors were identified by sequencing, 
revealing that 271 gRNAs were present in tumor genomic DNA, including 26 gRNAs 
targeting 21 known tumor suppressor genes. In support of the efficacy of this technique, 
two gRNAs targeted the well characterized tumor suppressor Trp53. Unexpectedly, 
Cdkn2b, which was not previously recognized as having a role in liver cancer, was 
targeted by three gRNAs. Mutations in the target region of Cdkn2b, as well as the 
development of tumors in mice injected with Cdkn2b-gRNA in the absence of a sensitizing 
background, confirmed that Cdkn2b functions as a tumor suppressor gene in the mouse 
liver. The identification of a new tumor suppressor gene supports the potential for 
CRISPR/Cas9 to be used for large-scale screens in vivo to identify drivers of liver 
cancer102. What was not clear in this manuscript was whether, similar to what was seen 
in the first in vivo multiplexed CRISPR/Cas9 screen103, substantial genetic changes from 
gRNA-mediated chromosomal cleavages were missed because of transient gRNA 
expression102.  
With a similar aim of targeting multiple tumor suppressors throughout the liver to 
study HCC, Wang et al. developed a CRISPR system that used pools of adeno-
associated viruses (AAVs)104. AAV virus is highly effective at infecting hepatocytes, 
approaching expression in 100% hepatocytes for certain serotypes105,106. As it only rarely 
integrates sequences into the genome, expression with AAV is transient. In the Wang 
study, each AAV was designed to express Cre, a gRNA targeting Trp53, and a gRNA 
targeting one of 49 putative tumor suppressor genes or 7 housekeeping control genes, 
with 4-5 gRNAs for each target104.  The authors injected the AAV library into lox-stop-lox-
Cas9 mice, which developed multiple large liver tumor nodules within four months. 
Because gRNA sequences likely had dissipated, the target genomic sites were examined 
to discover which mutations were linked to the tumors. The authors used an approach 
called molecular inversion probe (MIP) capture sequencing107 to assess for mutations in 
the ±70–base pair regions surrounding the predicted cut site for each of the gRNAs in 
their library. Analysis of co-occurring mutations revealed that beta-2 microglobulin 
(B2m) and KAT8 regulatory NSL complex subunit 1 (Kansl1) mutations were often found 
together. Notably, individually targeting B2m or Kansl1 using AAV-CRISPR did not 
induce tumorigenesis, while targeting both together accelerated tumorigenesis, validating 
their approach for the identification of gene-gene interactions that drive HCC. The 
drawbacks of this approach are that many mutations – such as those secondary to Trp53 
knockout or due to large chromosomal deletions or off target effects – may be missed by 
this technique. Indeed, the causative mutations were undetectable by MIP capture 
sequencing in a number of the tumors analyzed in this study. Furthermore, scale up to 
include hundreds or thousands of genes may not be feasible with this methodology.   
Instead of inducing permanent alterations in the genome with CRISPR/Cas9 to 
induce loss of function, or overexpressing cDNAs to assess gain of function, expression 
of specific genes can either be repressed (CRISPRi) or activated (CRISPRa) through 
systems employing dCas982,84 (Figure 3B). CRISPRi, which comprises dCas9 and 
gRNAs complementary to the target gene promoters, represses transcription either by 
steric inhibition of the transcriptional machinery by dCas9 alone or through fusion of 
dCas9 to the Kruppel-associated box (KRAB) transcriptional repressor82. Conversely, in 
the CRISPRa system, a transcriptional activator (TA) is either tethered to the dCas9 or 
recruited to minimal hairpin aptamers appended to the to the stem loop regions of the 
gRNA. CRISPRa induces the expression of the endogenous gene, which circumvents 
limitations of cDNA overexpression screens such as difficulty in building comprehensive 
libraries due to the variability in length of the cDNA sequences, and in capturing all of the 
gene isoforms82,108–110.  
The “first-generation” CRISPRa system consists of the TA VP64, derived from four 
tandem copies of the Herpes Simplex Viral Protein 16 (VP16), fused directly to the C 
terminus of dCas9. Subsequent refined versions are referred to as “second-generation” 
activators111. Two significant “second-generation” activators are the SunTag system and 
synergistic activation mediator (SAM). The SunTag version is composed of dCas9 fused 
to a multimer of short peptide epitopes that binds multiple copies of its cognate single-
chain variable fragment (scFv) domain, which is fused to VP64112. SAM harnesses the 
synergistic effects of multiple activation domains: VP64 is tethered to dCas9, while NF-
kB trans-activating subunit p65 and human heat shock factor 1 (HSF1) are bound to MS2, 
a bacteriophage coat protein that selectively binds the hairpin aptamers that are 
appended to the gRNA scaffold109. Both SAM and SunTag produce robust transcriptional 
activation from a single gRNA, making them practical for multiplexed, genome-wide gain-
of-function screens111.  
In order to streamline the CRISPRa system for use in in vivo screens targeted to 
specific tissues, including hepatocytes, we derived mice encoding a nuclease-deficient 
dCas9 allele fused to the ‘SunTag’ domain at the Rosa26 locus, termed dCas9+, with an 
upstream floxed stop cassette45. We then crossed them to Fah-/- mice and activated 
dCas9 expression specifically in hepatocytes by injecting AAV-Cre. Using SB transposon 
vectors, we generated a library of plasmids containing the TA scFv-VP64, an Fah 
expression cassette, and gRNAs targeting the promoters of Myc, tumor necrosis factor 
superfamily member 1a (Tnfrsf1a), solute carrier family 7 member 11 (Slc7a11), and 
Trp53, which we intravenously injected into the Fah-/-;dCas9+ mice. Nodules of MYC-
expressing, FAH-positive hepatocytes were found in Fah-/-;dCas9+ livers, indicating a 
robust and specific activation of expression of the endogenous gene. Myc gRNA 
sequences were highly significantly enriched in tumors, while Trp53 and Tnfrsf1a gRNAs 
were significantly depleted. Thus, the in vivo dCas9 system activated the Myc locus in 
hepatocytes and accelerated repopulation by these cells. The potent activation of MYC 
expression by CRISPRa strongly supports the potential for this system to be expanded 
to perform large scale screens of sets of genes belonging to a specific pathway 
simultaneously in vivo45. Furthermore, the dCas9+ mouse can be crossed to GEMMs of 
HCC, such as the HBsAg transgenic mouse113, to identify context-specific drivers of 
tumorigenesis associated with the multitude of HCC risk factors, as well as potential drug 
targets and mediators of resistance to chemotherapeutics. 
 
General considerations with genetic screens 
The following are important considerations for genetic screening in general: 
1. Genetic screens must take into account statistical power and the rate of false 
discovery. In the case of transposon insertional mutagenesis, mutation events in 
a particular gene must be observed in independently a number of times114. For 
cDNA, CRISPR, and RNAi experiments, the results also need to be observed 
independently in multiple replicates. There is the additional consideration of the 
“coverage” of the sequencing. In producing a screening library, there is a natural 
distribution of the components of the screen, and the lowly represented 
components may be lost by chance115. The standard for CRISPR screening on a 
genome scale, which often includes 100,000 plasmids or more84,116, is to screen 
and sequence to a depth of greater than 100-fold of the median amount of the 
plasmid117,118.  
2. Off-target or non-specific effects also need to be considered. In the case of 
transposons, “local hopping” is overcome by excluding genes located on the same 
chromosome as the donor transposon from the analyses, or by using independent 
transgenic mice with transposon donors on different chromosomes. In the case of 
RNAi and CRISPR screening, multiple shRNA or gRNA sequences are typically 
designed to target the same gene, which helps ensure that the observed effect is 
specific80,118.  
3. Finally, positive hits from a screen should be further validated in isolation, ideally 
with multiple modalities such as gene deletion, temporal or conditional control, or 
drug targeting117. 
 
Future directions 
Techniques for performing high-throughput genetic screens of cancer candidate 
genes have evolved dramatically over the past decade, with new technology enabling an 
exponential growth in the number and types of genes that can be screened. Liver cancer 
screens will continue to evolve as we develop new strategies to more accurately model 
HCC, classify its subtypes, and determine the responses to specific drug treatments. 
Transposon mutagenesis studies on different cancer-predisposed backgrounds have 
demonstrated the power of a predisposing mutation to influence which specific mutations 
become enriched in tumors. SB transposon and RNAi screens have provided clues to the 
mechanisms of sorafenib resistance, and CRISPR screens will likely be powerful tools in 
future studies to examine drivers and tumor suppressors in the setting of different types 
of liver injury, as well as drug resistance and sensitivity patterns. Re-framing the concept 
of HCC as a group of diseases, based on discoveries from these previous studies, will 
increase the power of screens to identify the clusters of genes cooperatively driving HCC 
in subsets of patients, and the alterations in genes leading to sensitivity or resistance to 
specific treatments, enabling a personalized approach to HCC treatment with 
pharmaceuticals.  
Finally, the technologies that have been applied so far – HTVI of plasmids, 
transposable elements, RNAi, and various types of CRISPR – are likely to evolve and 
improve in the decades to come. For example, future screens may examine cooperation 
between technologies to discover how combinations of gene activators and gene 
inhibitors interact. They may also include screens of libraries of expressed peptides or 
RNA molecules, which could accelerate the development of drugs that significantly 
improve the survival of patients with HCC. 
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